Objectives Despite the available therapies for treatment-resistant depression (TRD), there
are a limited number that are evidence-based and effective in this hard-to-treat population …

Background About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants and are considered to have treatment-resistant …

This post hoc analysis assessed the benefit–risk profile of esketamine nasal spray+ oral
antidepressant (AD) induction and maintenance treatment in patients with treatment …

Introduction This post hoc study assessed the evidence-base for esketamine nasal spray for
management of treatment-resistant depression (TRD) using number needed to treat (NNT) …

Objective: About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants. This study compared the efficacy and safety of …

Objective To present the first real-world data of patients with treatment-resistant depression
(TRD) treated with esketamine through a French cohort Temporary Authorisation for Use …

Purpose This Phase 3, multicenter study (NCT03434041) was conducted in primarily
Chinese patients with treatment-resistant depression (TRD) to support the registration of …

This narrative review aims to provide an overview of the current literature on the
pharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomer of …

Objective: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new
oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). Methods …

Aim: There is limited real-world evidence for patients with treatment-resistant depression
(TRD) receiving esketamine nasal spray. Methods: This retrospective cohort study used data …